

# **Global Clinical Next Generation Sequencing (NGS) Market Size, Growth, Share, Trends and Forecasts 2025 – 2032**

<https://marketpublishers.com/r/G1729DA913B2EN.html>

Date: June 2025

Pages: 210

Price: US\$ 4,000.00 (Single User License)

ID: G1729DA913B2EN

## **Abstracts**

### **Global Clinical Next Generation Sequencing (NGS) Market Size and Trends**

The global clinical next generation sequencing (NGS) market size was valued at USD 6.2 billion in 2024 and is projected to surpass around USD 15.2 billion by 2032, registering a CAGR of 13.6% over the forecast period of 2025 to 2032

### **Global Clinical Next Generation Sequencing (NGS) Market Growth Drivers**

Next Generation Sequencing (NGS) has revolutionized the field of genomics, providing unprecedented access to genetic information. This technological advancement facilitates the rapid sequencing of DNA and RNA, enabling a better understanding of various diseases, including cancer and genetic disorders. The global clinical NGS market is experiencing significant growth due to several driving factors.

One of the primary drivers of the market is the increasing demand for personalized medicine. As healthcare shifts towards precision interventions, NGS plays a crucial role in tailoring treatments to individual patients based on their genetic profiles. Furthermore, the declining costs associated with sequencing technologies make NGS more accessible to various healthcare facilities, thus expanding its adoption.

Significant investments in research and development are also stimulating growth in the global clinical NGS market. Governments and private entities are funneling resources into genomics research, which inevitably leads to innovative NGS applications. Additionally, the urgency to advance diagnostic capabilities to combat infectious diseases has further propelled the demand for NGS solutions.

## Global Clinical Next Generation Sequencing (NGS) Market Synopsis

This new market report presents an in-depth assessment of the global clinical next generation sequencing (NGS) market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global clinical next generation sequencing (NGS) market. The report also provides up-to-date historical market size data for the period 2023 – 2024 and an illustrative forecast to 2032 covering key market aspects like market value, share, analysis, and trends for the global clinical next generation sequencing (NGS) market.

The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for global clinical next generation sequencing (NGS) market segments, and a vivid forecast to 2032.

It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and therapy. The report also offers analysis and information according to categories such as market segments, application, technology, geographies, companies and competitive landscape. The report also provides a detailed description of the porter's five forces analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global clinical next generation sequencing (NGS) market.

The report concludes with the profiles of major market players in the global clinical next generation sequencing (NGS) market. The key market players are evaluated on various parameters such as company overview, technology focus, main competitive advantage, and company initiatives/news of the global clinical next generation sequencing (NGS) market.

The report will serve as a source for a 360-degree analysis in which various models will be thoroughly integrated. After a thorough study of the historical and current growth parameters, the growth prospects of the global clinical next generation sequencing (NGS) market are determined with utmost precision.

## **Global Clinical Next Generation Sequencing (NGS) Market: Segmentation**

Clinical Next Generation Sequencing (NGS) market is segmented on the basis of

product type, work flow, application, and region

### **Market Segment by Product Type**

Instruments

Workflow Solutions

Informatics

Services

### **Market Segment by Workflow**

Library Preparation

Sequencing

Data Analysis and Interpretation

Market Segment by Application

Genetics

Oncology

Infectious Diseases

Reproductive Health

Others

### **Market Segment by Region**

North America

Europe

Asia-Pacific

Middle East and Africa

Rest of World (ROW)

## **List of Key Players in the Global Clinical Next Generation Sequencing (NGS) Market**

Roche

Qiagen

Velsera

PacBio

Avitia

Axbio

Szaomics

Ignota Labs

Illumina Inc.

BGI Genomics

Sophia Genetics

10X Genomics

Variant Bio

Lucid Genomics

Wobble Genomics

Delfi Diagnostics

Milaboratories

Wittgen Biotechnologies

Thermo Fisher Scientific Inc.

Broken String Biosciences

## **Key Features of the Report**

The global clinical next-generation sequencing market provides granular level information about the market size, regional market share, historic market (2023 – 2024), and forecast (2025 – 2032)

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies.

The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.

The report tracks recent innovations, key developments, and start-up details that are actively working in the market.

The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.

The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter's five force analysis

## **Key Questions the Report Addresses**

How big is the clinical next generation sequencing market?

What is the current clinical next generation sequencing market size?

What is the major driving factor for the clinical next generation sequencing market?

Which factor is restraining the growth of the clinical next generation sequencing market?

Who are the key players in the clinical next generation sequencing market?

Which region has the biggest share in the clinical next generation sequencing market?

Which is the fastest growing region in the clinical next generation sequencing market?

## Contents

### **1. MARKET DEFINITION**

### **2. RESEARCH AND METHODOLOGY**

### **3. EXECUTIVE SUMMARY**

### **4. MARKET DYNAMICS**

#### 4.1 Growth Drivers

#### 4.2 Challenges

#### 4.3 Mergers & Acquisitions

### **5. GLOBAL CLINICAL NEXT GENERATION SEQUENCING MARKET OVERVIEW**

### **6. GLOBAL CLINICAL NEXT GENERATION SEQUENCING MARKET (2023 – 2032)**

### **7. GLOBAL CLINICAL NEXT GENERATION SEQUENCING MARKET SHARE ANALYSIS (2023 – 2032)**

#### 7.1 By Product Type

##### 7.1.1 By Instruments Region

##### 7.1.2 Workflow Solutions Region Share

##### 7.1.3 Informatics Region Share

##### 7.1.4 Services Region Share

#### 7.2 By Work Flow

#### 7.3 By Application

#### 7.4 By Region

### **8. BY PRODUCT**

#### 8.1 Instruments (2023 – 2032)

##### 8.1.1 North America

##### 8.1.2 Europe

##### 8.1.3 Asia-Pacific

##### 8.1.4 Middle East & Africa

##### 8.1.5 Rest of World (ROW)

#### 8.2 Workflow Solutions (2023 – 2032)

- 8.2.1 North America
- 8.2.2 Europe
- 8.2.3 Asia-Pacific
- 8.2.4 Middle East & Africa
- 8.2.5 Rest of World (Row)
- 8.3 Informatics (2023 – 2032)
  - 8.3.1 North America
  - 8.3.2 Europe
  - 8.3.3 Asia-Pacific
  - 8.3.4 Middle East & Africa
  - 8.3.5 Rest of World (ROW)
- 8.4 Services (2023 – 2032)
  - 8.4.1 North America
  - 8.4.2 Europe
  - 8.4.3 Asia-Pacific
  - 8.4.4 Middle East & Africa
  - 8.4.5 Rest of World (Row)

## **9. BY WORKFLOW**

- 9.1 Library Preparation
- 9.2 Sequencing
- 9.3 Data Analysis and Interpretation

## **10. BY APPLICATION**

- 10.1 Genetics
- 10.2 Oncology
- 10.3 Infectious Diseases
- 10.4 Reproductive Health
- 10.5 Others

## **11. BY REGION**

- 11.1 North America
- 11.2 Europe
- 11.3 Asia-Pacific
- 11.4 Middle East and Africa
- 11.5 Rest of World (ROW)



## **12. PORTER'S FIVE FORCES ANALYSIS**

- 12.1 Threat of New Entrants
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Threat of Substitute Products or Services
- 12.5 Intensity of Rivalry

## **13. SWOT ANALYSIS**

- 13.1 Strengths
- 13.2 Weaknesses
- 13.3 Opportunities
- 13.4 Threats

## **14. PRICING LANDSCAPE**

- 14.1 North America
- 14.2 Europe
- 14.3 Asia-Pacific
- 14.4 Latin America
- 14.5 Middle East
- 14.6 Africa
- 14.7 Key Factors Influencing Pricing Across Regions

## **15. COUNTRY POLICIES & REGULATION**

- 15.1 United States
- 15.2 Canada
- 15.3 France
- 15.4 Germany
- 15.5 Italy
- 15.6 Spain
- 15.7 United Kingdom
- 15.8 China
- 15.9 Japan
- 15.10 India
- 15.11 South Korea

15.12 United Arab Emirates (UAE)

15.13 South Africa

## **16. REIMBURSEMENT POLICIES**

16.1 United States

16.2 Canada

16.3 France

16.4 Germany

16.5 Italy

16.6 Spain

16.7 United Kingdom

16.8 China

16.9 India

16.10 Japan

16.11 South Korea

16.12 United Arab Emirates (UAE)

16.13 South Africa

## **17. KEY PLAYERS ANALYSIS**

17.1 Illumina

17.1.1 Technology Focus

17.1.2 Main Competitive Advantage

17.2 Thermo Fisher Scientific

17.2.1 Technology Focus

17.2.2 Main Competitive Advantage

17.3 BGI genomics

17.3.1 Technology Focus

17.3.2 Main Competitive Advantage

17.4 Roche

17.4.1 Technology Focus

17.4.2 Main Competitive Advantage

17.5 Sophia Genetics

17.5.1 Technology Focus

17.5.2 Main Competitive Advantage

17.6 Qiagen

17.6.1 Technology Focus

17.6.2 Main Competitive Advantage

## 17.7 Velsera

### 17.7.1 Technology Focus

### 17.7.2 Main Competitive Advantage

## 17.8 10X Genomics

### 17.8.1 Technology Focus

### 17.8.2 Main Competitive Advantage

## 17.9 PacBio

### 17.9.1 Technology Focus

### 17.9.2 Main Competitive Advantage

## 17.10 Avitia

### 17.10.1 Technology Focus

### 17.10.2 Main Competitive Advantage

## 17.11 Delfi Diagnostics

### 17.11.1 Technology Focus

### 17.11.2 Main Competitive Advantage

## 17.12 Variant Bio

### 17.12.1 Technology Focus

### 17.12.2 Main Competitive Advantage

## 17.13 Wittgen Biotechnologies

### 17.13.1 Technology Focus

### 17.13.2 Main Competitive Advantage

## 17.14 Axbio

### 17.14.1 Technology Focus

### 17.14.2 Main Competitive Advantage

## 17.15 Szaomics

### 17.15.1 Technology Focus

### 17.15.2 Main Competitive Advantage

## 17.16 Ignota Labs

### 17.16.1 Technology Focus

### 17.16.2 Main Competitive Advantage

## 17.17 Lucid Genomics

### 17.17.1 Technology Focus

### 17.17.2 Main Competitive Advantage

## 17.18 Wobble Genomics

### 17.18.1 Technology Focus

### 17.18.2 Main Competitive Advantage

## 17.19 Broken String Biosciences

### 17.19.1 Technology Focus

### 17.19.2 Main Competitive Advantage

## 17.20 Milaboratories

### 17.20.1 Technology Focus

### 17.20.2 Main Competitive Advantage

## I would like to order

Product name: Global Clinical Next Generation Sequencing (NGS) Market Size, Growth, Share, Trends and Forecasts 2025 – 2032

Product link: <https://marketpublishers.com/r/G1729DA913B2EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1729DA913B2EN.html>